Reactome | Signaling by ERBB2 KD Mutants

Schema > Pathway > Entries

Signaling by ERBB2 KD Mutants Show undefined attributes

authored	[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
created	[InstanceEdit:9664566] Orlic-Milacic, Marija, 2019-10-25
crossReference	[DatabaseIdentifier:12819465] BioModels Database:BIOMD0000000255 [DatabaseIdentifier:12020745] Mondo:0004992 [DatabaseIdentifier:12819433] BioModels Database:BIOMD0000000653 [DatabaseIdentifier:12819435] BioModels Database:BIOMD0000000656 [DatabaseIdentifier:12819561] BioModels Database:BIOMD0000000594 [DatabaseIdentifier:12819437] BioModels Database:BIOMD0000000648 [DatabaseIdentifier:12819563] BioModels Database:BIOMD0000000223 [DatabaseIdentifier:12819471] BioModels Database:BIOMD0000000175 [DatabaseIdentifier:12819441] BioModels Database:BIOMD0000000655 [DatabaseIdentifier:12819565] BioModels Database:BIOMD0000000595 [DatabaseIdentifier:12819443] BioModels Database:BIOMD0000000652 [DatabaseIdentifier:12819431] BioModels Database:BIOMD0000000883 [DatabaseIdentifier:12819481] BioModels Database:BIOMD0000000399 [DatabaseIdentifier:12819483] BioModels Database:BIOMD0000000019 [DatabaseIdentifier:12819451] BioModels Database:BIOMD0000000477 [DatabaseIdentifier:12819485] BioModels Database:BIOMD0000000424 [DatabaseIdentifier:12819445] BioModels Database:BIOMD0000000654
dbId	9664565
disease	[Disease:1500689] cancer
displayName	Signaling by ERBB2 KD Mutants
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
eventOf	[Pathway:R-HSA-1227990] Signaling by ERBB2 in Cancer - Homo sapiens
hasDiagram	true
hasEHLD	false
hasEvent	[Reaction:R-HSA-9664567] ERBB2 KD mutants heterodimerize - Homo sapiens [Reaction:R-HSA-9664588] ERBB2 KD mutants trans-autophosphorylate - Homo sapiens [Reaction:R-HSA-9664646] Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K - Homo sapiens [Reaction:R-HSA-9664664] PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 converts PIP2 to PIP3 - Homo sapiens [Reaction:R-HSA-9664918] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:GAB1 - Homo sapiens [Reaction:R-HSA-9664933] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K - Homo sapiens [Reaction:R-HSA-9664940] PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3 - Homo sapiens [Reaction:R-HSA-9664950] Phosphorylated heterodimers of ERBB2 KD mutants bind SHC1 - Homo sapiens [Reaction:R-HSA-9664976] Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1 - Homo sapiens [Reaction:R-HSA-9664983] Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 - Homo sapiens [Reaction:R-HSA-9664991] RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants - Homo sapiens [Reaction:R-HSA-9665000] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1 - Homo sapiens [Reaction:R-HSA-9665009] RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR - Homo sapiens [Reaction:R-HSA-9665034] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind PLCG1 - Homo sapiens [Reaction:R-HSA-9665032] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR phosphorylate PLCG1 - Homo sapiens [Reaction:R-HSA-9665121] ERBB2 KD mutants bind TKIs - Homo sapiens [Reaction:R-HSA-9649393] ERBB2 KD mutants bind trastuzumab - Homo sapiens
isInDisease	true
isInferred	false
lastUpdatedDate	2023-06-07
literatureReference	[LiteratureReference:9646445] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer [LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9646515] Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma [LiteratureReference:9646518] COSMIC: somatic cancer genetics at high-resolution [LiteratureReference:9646647] Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface [LiteratureReference:9646654] Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer [LiteratureReference:9646758] Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification [LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation [LiteratureReference:9646940] Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy [LiteratureReference:9647018] Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies [LiteratureReference:9647024] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas [LiteratureReference:9646931] Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [LiteratureReference:9646947] Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma [LiteratureReference:9646957] Integrated genomic analyses of ovarian carcinoma [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor [LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity [LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
maxDepth	2
modified	[InstanceEdit:12819426] Weiser, Joel, 2026-02-23
name	Signaling by ERBB2 KD Mutants
normalPathway	[Pathway:R-HSA-1227986] Signaling by ERBB2
releaseDate	2019-12-10
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
schemaClass	Pathway
species	[Species:48887] Homo sapiens
stId	R-HSA-9664565
summation	[Summation:9646452] Mutations in the kinase domain (KD) of ERBB2 result in const...
updateTrackers	[UpdateTracker:9835787] Update Tracker - [Pathway:9664565] Signaling by ERBB2 KD Mutants - v85:[modifyText, updateContainedRLE]

Referrals

(hasEvent)	[Pathway:R-HSA-1227990] Signaling by ERBB2 in Cancer
(updatedInstance)	[UpdateTracker:9835787] Update Tracker - [Pathway:9664565] Signaling by ERBB2 KD Mutants - v85:[modifyText, updateContainedRLE]

Cite Us!